Hepatitis Foundation International

The Hepatitis Foundation International (www.HepatitisFoundation.org) is a 501 c 3 non-profit organization established in 1994 dedicated to promoting health and wellness, reducing the incidence of preventable liver-related chronic diseases and lifestyles...

[hepficonnect]

Recent data published in Hepatology suggest systematic inflammation as the main driver of acute-on-chronic liver failure in patients with decompensated cirrhosis. “The current study supports the systematic inflammation hypothesis of acute decompensation and acute-on-chronic liver failure in cirrhosis,” Joan Clària, MD, clinical biochemist in the Hospital Clinic of Barcelona,

[hepficonnect]

Create a new survey on your own or with others at the same time. Choose from a variety of survey types and analyze results in Google Forms. Free from Google.

[hepficonnect]

America’s #FQHCs are innovators in community health. Let's celebrate their success during #NHCW16! #CHCsInnovate http://thndr.me/tsSLcS

[hepficonnect]

[hepficonnect]

Fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.

[hepficonnect]

I’m supporting #NOhep on #WorldHepDay! Sign up to eliminate viral hepatitis & save 7.1 million lives by 2030! http://thndr.me/ZSmxnU

[hepficonnect]

[hepficonnect]

[hepficonnect]

HHS Announces New Plans to Combat the U.S. Opioid Epidemic

Actions include expanding access to buprenorphine treatment and launching more than a dozen new studies on drug abuse and chronic pain.

[hepficonnect]

New teleclinics linking regular health care providers with liver specialists on the web may be the future of hepatitis C virus (HCV) care in the United States.

[hepficonnect]

[hepficonnect]

MassHealth to pay for hepatitis C drugs for all infected members - The Boston Globe

The state had previously required that many patients show evidence of liver damage before it would pay for the powerful drugs.

[hepficonnect]

The FDA has verbally notified Regulus Therapeutics that its investigational new drug RG-101 for the treatment of chronic hepatitis C virus infection has been placed on clinical hold after a second patient reported a serious adverse event, according to a news release.The FDA initiated the clinical hold after Regulus reported the serious adverse event of jaundice, which occurred in a patient with

[hepficonnect]

Hepatitis C virus infection appeared associated with an increased risk for certain nonoropharyngeal cancers and human papillomavirus-positive oropharyngeal cancer, according to results of a case–control study. In 2009, The University of Texas MD Anderson Cancer Center opened the first clinic in the United States to manage HCV infection in patients with cancer.

[hepficonnect]

Evidence of fibrosis was common in older patients with hepatitis C virus genotype 3 infection, indicating fibrosis progresses with age and this patient population should be treated as often and with the same medications as other severe HCV patient populations, according to data presented at the British Society of Gastroenterology Annual Meeting. According to Keeley Fairbrass, of the Digestive

[hepficonnect]

[hepficonnect]

In a real-world cohort of veterans with hepatitis C virus infection genotype 1, Harvoni-based therapy produced sustained virologic response rates over 90%, according to published findings.“HCV disproportionately affects the veteran population, and this population if often underrepresented in clinical trials, largely due to complicating comorbidities. … With the rapid uptake of